Open AccessReaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients
Author(s) -
Rannveig Skrunes,
Einar Svarstad,
Kristin Kampevold Larsen,
Sabine Leh,
Camilla Tøndel
Publication year - 2016
Publication title -
nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfw094
Subject(s) - fabry disease , globotriaosylceramide , medicine , urology , renal function , clearance , kidney disease , disease
Agalsidase-α 0.2 mg/kg every other week (eow) and agalsidase-β 1.0 mg/kg/eow are licensed in Europe as equipotent treatment of the α-galactosidase deficiency in Fabry disease. This case series describes the effects of agalsidase dose adjustments in serial kidney biopsies in switch patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom